Search research articles
Contact Us
Filters
Showing results (861-870 of 888) with videos related to
Page
of 89
Sort By:
JCO Oncology Practice
|
September 28, 2020
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC
Brittany M Szymaniak, Lauren A Facchini, Veda N Giri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2018
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal, Jiaoti Huang, Joshi J Alumkal, et al.
European Urology Open Science
|
December 22, 2021
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
Karen A Autio, Emmanuel S Antonarakis, Tina M Mayer, et al.
NPJ Precision Oncology
|
July 7, 2025
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer
Anbarasu Kumaraswamy, Ya-Mei Hu, Joel A Yates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2022
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
Phuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 20, 2020
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
Joshi J Alumkal, Duanchen Sun, Eric Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 24, 2020
Autoantibody Landscape in Patients with Advanced Prostate Cancer
William S Chen, Winston A Haynes, Rebecca Waitz, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases
|
February 27, 2016
Introduction and enzootic of A/H5N1 in Egypt: Virus evolution, pathogenicity and vaccine efficacy ten years on
E M Abdelwhab, M K Hassan, A S Abdel-Moneim, et al.
European Urology
|
March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Prostate Cancer and Prostatic Diseases
|
February 27, 2019
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
Nicholas G Nickols, Ramin Nazarian, Shuang G Zhao, et al.
Page
of 89
Search research articles
Search
Showing results (861-870 of 888) with videos related to
Sort By:
Page
of 89
JCO Oncology Practice
|
September 28, 2020
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC
Brittany M Szymaniak, Lauren A Facchini, Veda N Giri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2018
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal, Jiaoti Huang, Joshi J Alumkal, et al.
European Urology Open Science
|
December 22, 2021
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
Karen A Autio, Emmanuel S Antonarakis, Tina M Mayer, et al.
NPJ Precision Oncology
|
July 7, 2025
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer
Anbarasu Kumaraswamy, Ya-Mei Hu, Joel A Yates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2022
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
Phuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 20, 2020
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
Joshi J Alumkal, Duanchen Sun, Eric Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 24, 2020
Autoantibody Landscape in Patients with Advanced Prostate Cancer
William S Chen, Winston A Haynes, Rebecca Waitz, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases
|
February 27, 2016
Introduction and enzootic of A/H5N1 in Egypt: Virus evolution, pathogenicity and vaccine efficacy ten years on
E M Abdelwhab, M K Hassan, A S Abdel-Moneim, et al.
European Urology
|
March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Prostate Cancer and Prostatic Diseases
|
February 27, 2019
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
Nicholas G Nickols, Ramin Nazarian, Shuang G Zhao, et al.
Page
of 89